biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human, mouse, rat
technique(s)
immunoprecipitation (IP): suitable, western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... TFAM(7019)
mouse ... Tfam(21780)
General description
TFAM(也称mtTFA)是一种线粒体转录因子,它是线粒体转录的关键激活剂,也参与线粒体基因组复制。小鼠研究表明线粒体基因组拷贝数的调节和胚胎发育都需要该基因产物。
观测值〜27 kDa
Immunogen
His标记的重组蛋白,对应于小鼠mtTFA。
Application
使用经验证可用于蛋白质印迹&IP的该兔多克隆抗-TFAM抗体检测TFAM。
免疫沉淀分析:一个来自独立实验室的代表性批次使C2C12细胞裂解液做工的Chd2免疫沉淀(Harada,A.,et al.(2012).
研究子类别
转录因子
转录因子
研究类别
表观遗传学&核功能
表观遗传学&核功能
Physical form
兔多克隆抗血清,含0.05%叠氮化钠。
未纯化
Preparation Note
自收到之日起在-20°C可稳定保存1年。
使用建议:收货后,在取下瓶盖之前,将小瓶离心并轻轻混合溶液。分装到微量离心管中,并储存于-20°C。避免反复冻融循环,以免损坏IgG和影响产品性能。
使用建议:收货后,在取下瓶盖之前,将小瓶离心并轻轻混合溶液。分装到微量离心管中,并储存于-20°C。避免反复冻融循环,以免损坏IgG和影响产品性能。
Analysis Note
通过蛋白质印迹法在C2C12 细胞裂解物中进行评价。
蛋白质印迹分析:该抗体的1:1,000 稀释液在10 µg C2C12细胞裂解液中检测到TFAM。
蛋白质印迹分析:该抗体的1:1,000 稀释液在10 µg C2C12细胞裂解液中检测到TFAM。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明,否则我们的产品仅供研究使用,不得用于任何其他目的,包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
Still not finding the right product?
存储类别
10 - Combustible liquids
wgk
WGK 1
Jong-Hyuk Lee et al.
Experimental & molecular medicine, 54(12), 2135-2147 (2022-12-07)
PARPs play fundamental roles in multiple DNA damage recognition and repair pathways. Persistent nuclear PARP activation causes cellular NAD+ depletion and exacerbates cellular aging. However, very little is known about mitochondrial PARP (mtPARP) and poly ADP-ribosylation (PARylation). The existence of
Krishna Prahlad Maremanda et al.
Toxicology and applied pharmacology, 385, 114788-114788 (2019-11-05)
Cigarette smoke (CS)-induced lung inflammation and Chronic Obstructive Pulmonary disease (COPD) involves mitochondrial dysfunction. Mesenchymal stem cells (MSC) and MSC-derived exosomes (EXO) are reported to show therapeutic effects in many animal models of inflammation and injury. In the present study
Nicole DeFoor et al.
Scientific reports, 13(1), 15339-15339 (2023-09-16)
SARS-CoV-2 causes the severe respiratory disease COVID-19. Remdesivir (RDV) was the first fast-tracked FDA approved treatment drug for COVID-19. RDV acts as an antiviral ribonucleoside (adenosine) analogue that becomes active once it accumulates intracellularly. It then diffuses into the host
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| ABE483 | 04053252927942 |